Skip to main content
. Author manuscript; available in PMC: 2015 Mar 1.
Published in final edited form as: J Am Acad Dermatol. 2013 Dec 22;70(3):481–488. doi: 10.1016/j.jaad.2013.10.018

Table II.

UVA1 phototherapy protocol and dosing regimen

1. Patients should be treated 2–3 limes per week.
2. Treat whole body except for face and genitals.
3. Goggles should be worn at all times by the patient and the phototherapist.
4. For skin phototypes ≤ Fitzpatrick III. start at 40 J/cm2. For skin phototypes ≥ IV, start at 70 J/cm2.. Increase by 10–20 J/cm2 per treatment to a maximum of 120 J/cm2. No need to apply emollient.
5. Maintain dose as long as no erythema occurs.
 If sunburn erythema should occur:
  • Mild to moderate- decrease dose by 10%. Once the patient tolerates the reduced dose without erythema, increase as tolerated per above protocol.
  • Severe- notify the PI who will evaluate the patient.
  • If erythema is a repeated problem, notify physician. Erythema is unusual with UVA1 light treatments. A recurrent problem warrants a physician evaluation.
6. Assess after 10–15 treatments*
  • Good response- maintain dose (no extension or new lesions and erythema and signs of disease activity improved
  • Partial response – to maximal dose (120 J/cm2) per protocol, no new lesions, minimal extension of exisiting lesions, and/or persistent erythema persistent/worsening erythema
  • No response- worsening (new lesions or lesion extension, persistent/worsening erythema); stop UVA1 phototherapy and consider alternative therapy
7. Reassess after another 10–15 treatments (for a total of 20–30 treatments or 6 weeks of treatment)**
  • Good response or maximal improvement (no new lesions or extension of existing lesions; complete resolution of erythema and signs of activity, i.e. erythema) - stop UVA1
  • Partial or no response- discontinue UVA1 and consider alternative therapy
*

Patients are assessed by serial photography and by 1 investigator (HJ).

**

Existing studies support satisfactory results with UVA1 delivered over 30–40 sessions.10, 1213 This protocol is derived from existing evidence for the use of UVA1 in morphea.